We also demonstrated that high ATP1B1 expression was an unfavorable prognostic biomarker for CN-AML patients, based on clinical and molecular characteristics prior to treatment and OS/EFS across the entire cohort or within ELN categories. This evidence concerns the gene ATP1B1 and acute myeloid leukemia.